Molecular Pathology of Gliomas.
1p19q loss
ATRX mutation
BRAF V600E mutation
BRAF fusion
Histone H3 K27M mutation
IDH1/2 mutation
Journal
Clinics in laboratory medicine
ISSN: 1557-9832
Titre abrégé: Clin Lab Med
Pays: United States
ID NLM: 8100174
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
31
5
2024
Statut:
ppublish
Résumé
Gliomas are the most common adult and pediatric primary brain tumors. Molecular studies have identified features that can enhance diagnosis and provide biomarkers. IDH1/2 mutation with ATRX and TP53 mutations defines diffuse astrocytomas, whereas IDH1/2 mutations with 1p19q loss defines oligodendroglioma. Focal amplifications of receptor tyrosine kinase genes, TERT promoter mutation, and loss of chromosomes 10 and 13 with trisomy of chromosome 7 are characteristic features of glioblastoma and can be used for diagnosis. BRAF gene fusions and mutations in low-grade gliomas and histone H3 mutations in high-grade gliomas also can be used for diagnostics.
Identifiants
pubmed: 38821638
pii: S0272-2712(23)00086-0
doi: 10.1016/j.cll.2023.08.009
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-159Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure Advisory Board Member - Arima Genomics; InnoSIGN Scientific Advisor and Stock Ownership - HaloDX; Heidelberg Epignostix.